Massachusetts General Hospital: Multiple Myeloma trials

The registry lists 32 Multiple Myeloma studies with Massachusetts General Hospital as lead sponsor. 6 are open to participants now and 7 have results posted.

Phase 1 11Phase 2 14No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple MyelomaNot yet recruitingNCT07247097Phase 2
• Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingNCT07032714Phase 1
• ELISA in Relapsed/Refractory MMRecruitingNCT06832865Phase 2
• Elranatamab in R/R Multiple MyelomaRecruitingNCT06138275Phase 2
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
• Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular TherapyRecruitingNCT05646576Not applicable
• KRDI in Transplant-Eligible MMActive, not recruitingNCT04430894Phase 2Results posted
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal DiseaseCompletedNCT02158052Not applicableResults posted
• Meloxicam vs Placebo for MobilizationCompletedNCT02003625Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Bone Marker Assessment of Multiple Myeloma Patients Treated With AminobisphosphonatesCompletedNCT00577642Phase 2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple MyelomaActive, not recruitingNCT06073353Not applicable
• Biomarker for Infection Risk in CLL and MMActive, not recruitingNCT05844033
• Covid-19 Vaccine Responsiveness in MM and WaldenstromCompletedNCT04830046
• Multiple Myeloma (MM) Quality of Life (QOL) StudyStatus unknownNCT04388735
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT03657420Phase 1
• A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT03091257Phase 1
• A Study of Denosumab in Multiple Myeloma Patients With Renal InsufficiencyCompletedNCT02833610Phase 2
• A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingNCT02718833Phase 2
• Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
• XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseCompletedNCT01582295Phase 1
• Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT01562405Phase 1
• Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell TransplantTerminatedNCT00909948Phase 1
• Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)CompletedNCT00854139Phase 1
• RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaCompletedNCT00729638Phase 1
• Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.CompletedNCT00299780Phase 1
• Phase I Study of Sequential Cord Blood TransplantsCompletedNCT00299767Phase 1
• Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
• Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113828Phase 2
• Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2